Florida blood bank, OneBlood, to use to INTERCEPT System to reduce the risk of transfusion-transmitted infection

Cerus Corporation announced last week that OneBlood, Inc. has signed a multi-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. The INTERCEPT System reduces the risk of transfusion-transmitted infection in platelet and plasma components by inactivating a broad spectrum of viruses, gram-positive and gram-negative bacteria, spirochetes, parasites and leukocytes. "Safety of the blood ["]